Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AF74 | ISIN: US44842L1035 | Ticker-Symbol: H7T1
Siehe auch HUTCHMED CHINA LIMITED
Tradegate
06.06.25 | 16:02
13,300 Euro
-1,48 % -0,200
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
HUTCHMED CHINA LIMITED ADR Chart 1 Jahr
5-Tage-Chart
HUTCHMED CHINA LIMITED ADR 5-Tage-Chart
RealtimeGeldBriefZeit
13,40013,50006.06.
13,30013,60006.06.

Aktuelle News zur HUTCHMED CHINA LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoHutchmed new drug application accepted in China2
DoHutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance-
DoCLSA: HUTCHMED Rating Kept at Outperform on Decent Savolitinib Research Data2
HUTCHMED CHINA LIMITED ADR Aktie jetzt für 0€ handeln
DoHUTCHMED Last Leaps ~5%, While INNOVENT BIO Falters; Application for Combination Therapy for RCC Accepted1
DoNew Drug Application for INNOVENT BIO's Sintilimab Combination with HUTCHMED's Fruquintinib Accepted in CN1
DoHUTCHMED's NDA For Fruquintinib-sintilimab Combo In Renal Cancer Accepted By China's NMPA308BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) and Innovent Biologics, Inc. announced that the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment...
► Artikel lesen
DoHUTCHMED (China) Limited: HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma2
DoHUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED AND INNOVENT JOINTLY ANNOUNCE NDA ACCEPTANCE IN CHINA FOR FRUQUINTINIB COMBINATION WITH SINTILIMAB ...2
MoHutchmed China Ltd - HUTCHMED Highlights SACHI Phase III Data at ASCO-
MoHUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED HIGHLIGHTS SACHI PHASE III STUDY DATA PRESENTED AT THE 2025 ASCO ANNUAL MEETING1
30.05.HUTCHMED Ltd - 6-K, Report of foreign issuer2
30.05.HUTCHMED (00013): TOTAL VOTING RIGHTS-
30.05.Hutchmed China Ltd - Total Voting Rights-
23.05.HUTCHMED Ltd - 6-K, Report of foreign issuer1
23.05.HUTCHMED to showcase new cancer study data at ASCO meeting1
23.05.HUTCHMED wird neue Krebsstudiendaten auf ASCO-Tagung präsentieren4
23.05.Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ASCO-
23.05.HUTCHMED to Present Multiple Research Data at ASCO Annual Meeting by End-May1
23.05.HUTCHMED (China) Limited: HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting1
23.05.HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED HIGHLIGHTS CLINICAL DATA TO BE PRESENTED AT THE 2025 ASCO ANNUAL MEETING1
Weiter >>
188 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1